In a dramatic development, the Federal Trade Commission yesterday announced its highly anticipated lawsuit against the World Professional Association for Transgender Health (WPATH). This is a group whose recommendations, known as the “Standards of Care”, guide the treatment of minors and adults who feel discomfort in their sexed bodies and seek drugs and surgeries to alter them.

If the lawsuit is successful, it could spell the end for the embattled activist-medical group. But that wouldn’t be all. WPATH has spent the past two decades infiltrating bona fide medical groups such as the Endocrine Society with the goal of getting them to launder its credibility by staking their own on it. WPATH’s downfall would thus likely trigger a larger collapse, bringing public scandal — and potentially legal and financial liability — to other doctor groups.

In his first week in office, President Trump ordered federal agencies to curb the medical transition of minors, including the FTC, which is tasked with policing unfair or deceptive practices. The FTC followed up with a July 2025 workshop on the risks of so-called “gender-affirming care” for minors.

Yesterday’s lawsuit, filed in the United States District Court for the Northern District of Texas, is the culmination of that process. The FTC is joined by Alaska, Iowa, Nebraska, and Texas, which allege that WPATH facilitated violations of their own consumer protection and anti-fraud laws. The choice of venue is strategic: Texas’s northern district is a Republican-friendly court, and WPATH is incorporated in that state.

Are the plaintiffs on strong legal footing? The short answer is yes. In 2024, internal WPATH communications obtained through court discovery in Boe v. Marshall, a lawsuit involving Alabama’s ban on pediatric transition, surfaced unambiguous proof of medical scandal. First, WPATH had commissioned systematic reviews of evidence on treatment outcomes but then suppressed their publication upon discovering that this would not support its preferred approach. WPATH leaders confided privately that they were “caught on the wrong foot”.

WPATH then sought to cover its tracks. In the final version of its eighth and current Standards of Care (SOC-8), it claimed a systematic review of evidence on adolescent outcomes was “not possible”. The same pattern emerged over age limits. Within hours of SOC-8’s publication, WPATH removed minimum ages for hormonal and surgical interventions (except phalloplasty), reportedly under pressure from Admiral Rachel Levine and the American Academy of Pediatrics.

SOC-8 states that all recommendations underwent the Delphi consensus process, but committee chair Eli Coleman has acknowledged that this was not the case. Meanwhile, adolescent chapter co-chair Scott Leibowitz is alleged to have misled WPATH members about the removal of age limits after helping develop the organisation’s public relations strategy.

Further, WPATH claimed that it adhered to accepted standards for identifying and managing conflicts of interest among guideline authors, but it later transpired that most SOC-8 authors had unmanaged conflicts of interest, in some cases financial, and that WPATH’s own methodological advisors complained of this.

In 2025, WPATH conference videos demonstrated further evidence of the organisation operating wholly outside the realm of evidence-based medicine and medical ethics. As one WPATH physician, believing she was among trusted peers, admitted, “we’re all just winging it.”

The FTC alleges that WPATH operates in the financial interests of its members by promoting medical transition services for children and adolescents. According to the complaint, SOC-8 serves as the vehicle for marketing these interventions as “consensus-based” and “medically necessary” care. The agency claims WPATH misrepresented key aspects of treatment, including the assertion that puberty blockers are fully reversible. It also challenges what it describes as misleading terminology surrounding surgical outcomes and faults WPATH for failing to transparently disclose significant risks.

If the FTC’s lawsuit is successful, it would effectively bar WPATH from promoting SOC-8 and its broader medical approach. In a notable twist, the agency cites comments submitted by WPATH supporters during its public consultation as evidence of consumer deception, arguing that many parents, patients, and clinicians expressed confidence in SOC-8’s scientific authority precisely because they were misled about how it was developed.

Trump administration initiatives in this area have frequently stalled in court. But supporters of this lawsuit argue that this case is different: the venue is favourable, the legal theory is plausible, and the evidentiary record is unusually strong. If they are right, WPATH’s days are numbered.